Shares of Genocea Biosciences Inc. (NASDAQ:GNCA) dropped 1.5% on Thursday . The stock traded as low as $5.15 and last traded at $5.19, with a volume of 61,577 shares traded. The stock had previously closed at $5.27.

GNCA has been the topic of several recent research reports. FBR & Co reissued a “buy” rating on shares of Genocea Biosciences in a report on Friday, June 10th. Zacks Investment Research raised Genocea Biosciences from a “hold” rating to a “buy” rating and set a $4.75 price objective on the stock in a report on Tuesday, July 5th. One research analyst has rated the stock with a hold rating and five have given a buy rating to the company. The stock currently has a consensus rating of “Buy” and an average price target of $17.95.

The company’s 50 day moving average is $4.57 and its 200 day moving average is $4.45. The company’s market cap is $140.25 million.

Genocea Biosciences (NASDAQ:GNCA) last issued its quarterly earnings results on Thursday, August 4th. The company reported ($0.39) EPS for the quarter, beating the consensus estimate of ($0.44) by $0.05. On average, equities research analysts forecast that Genocea Biosciences Inc. will post ($1.63) earnings per share for the current year.

Genocea Biosciences, Inc is a biopharmaceutical company. The Company discovers and develops vaccines and immunotherapies. It uses its discovery platform, AnTigen Lead Acquisition System (ATLAS), to design vaccines and immunotherapies that act, in part, through T cell (or cellular) immune responses. The Company operates through business of developing and commercializing vaccines segment.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.